Increasing Incidence of HPV Related Oropharyngeal Cancers
Authors:
H. Binková 1; Z. Horáková 1; R. Kostřica 1; K. Veselý 2
Authors‘ workplace:
Klinika otorinolaryngologie a chirurgie hlavy a krku LF MU a FN u svaté Anny v Brně
1; I. patologicko-anatomický ústav LF MU a FN u svaté Anny v Brně
2
Published in:
Otorinolaryngol Foniatr, 64, 2015, No. 4, pp. 205-212.
Category:
Review Article
Overview
The incidence of head and neck tumors has generally stagnant or slightly decreasing character, which is mainly attributed to the declining prevalence of smoking. This trend is not true for oropharyngeal carcinoma (OPC), whose incidence is increasing rapidly, on the contrary, in the Czech Republic is now 3 times higher than 30 years ago. This increase is directly related to the growing group of OPC (45-95%), which etiology is related to Human Papilloma Virus (HPV) infection. HPV positive OPC represent etiologically, clinically and epidemiologically distinct group of patients, which is characterized by younger age, better response to treatment and a significantly better prognosis. Treatment standards do not reflect HPV status so far; however, an extensive research focuses on possible treatments des –intensification of HPV positive OPC to reduce the effects of mutilating radical and conservative surgical treatment. The possibility of preventive vaccination of adolescent young men and women is also being explored. Unlike cervical cancer, where preventive programs have already brought results in declining incidence trends, viral etiology of cancer tonsils and base of the tongue attracts still little attention. In public education should be emphasized the importance of the risk of HPV infection and the associated responsible approach when choosing sexual partners, especially for orogenital sex and preventive vaccination.
Keywords:
oropharyngeal cancer, HPV infection, oral sex, prognosis, prevention
Sources
1. Ang, K. K., Harris, J., Wheeler, R. et al.: Human papillomavirus and survival of patients with oropharyngeal cancer. New England Journal of Medicine, 363, 2010, 1, s. 24-35.
2. Binkova, H., Horakova, Z., Kostrica, R. et al.: HPV in prognosis and therapy of oropharyngeal cancer. Florence, Eurogin 2013: HPV at a crossroads - 30 years of research and practice, s. 313.
3. Binková, H., Horáková, Z., Tóthová, E. et al.: Záchovný protokol u nádorů orofaryngu. Otorinolaryng. a Foniat. /Prague/, 59. 2010, 3, s. 114-121.
4. Bishop, J. A., Ma, X. J., Wang, H. et al.: Detection of transcriptionally active high-risk HPV in patients with head and neck squamous cell carcinoma as visualized by a novel E6/E7 mRNA in situ hybridization method. Am. J. Surg. Pathol., 36, 2012, 12, s. 874-882.
5. D’Souza, G., Agrawal, Y., Halpern, J. et al.: Oral sexual behaviors associated with prevalent oral human papillomavirus infection. Journal of Infectious Diseases. 2009, 199, 9, s. 1263-1269.
6. D’Souza, G., Kreimer, A., Viscidi, R. et al.: Case–kontrol study of human papillomavirus and oropharyngeal cancer. N. Engl. J. Med., 365, 2007, s. 1944-1956.
7. Dušek, L., Mužík, J., Kubásek, M. et al.: Epidemiologie zhoubných nádorů v České republice [online]. Masarykova univerzita,. [Online] [cit. 2014-5-04] 2005. http://www.svod.cz/analyse.php?modul=incmor#.
8. Fakhry, C., Rosenthal, B. T., Clark, D. P. et al: Associations between oral HPV16 infection and cytopathology: evaluation of an oropharyngeal "Pap-test equivalent" in high-risk populations. Cancer Prev. Res., 2011, 4, s. 1378-1384.
9. Fakhry, C., Westra, W. H., Li, S. et al.: Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. Journal of the National Cancer Institute, 100, 2008, 4, s. 261-269.
10. Gillison, M. L., D’Souza, G., Westra, W. et al.: Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. Journal of the National Cancer Institute, 100, 2008, 6, s. 407-420.
11. Gillison, M. L., Koch, W. M., Capone, R. B. et al.: Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J. Natl. Cancer Inst., 92, 2000, 9, s. 709-720.
12. Goldenberg, D., Begum, S., Westra, W. H. et al.: Cystic lymph node metastasis in patients with head and neck cancer: an HPV-associated phenomenon. Head and Neck, 30, 2008, 7, s. 898-903.
13. Hafkamp, H. C., Manni, J. J., Haesevoets, A. et al.: Marked differences in survival rate between smokers and nonsmokers with HPV 16-associated tonsillar carcinomas. International Journal of Cance, 122, 2008, 12, s. 2656-2664.
14. Häfner, N., Driesch, C., Gajda, M. et al.: Integration of the HPV16 genome does not invariably result in high levels of viral oncogene transcripts. Oncogene, 27, 2008, 6 (11), s. 1610-1617.
15. Hammarstedt, L., Lindquist, D., Dahlstrand, H. et al.: Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer. International Journal of Cancer, 119, 2006, 11, s. 2620-2623.
16. Heck, J. E., Berthiller, J., Vaccarella, S. et al.: Sexual behaviours and the risk of head and neck cancers: a pooled analysis in the International Head and Neck Cancer Epidemiology (INHANCE) consortium. International Journal of Epidemiology, 39, 2010, 1, s. 166-181.
17. Herrero, R., Castellsagué, X., Pawlita, M. et al.: Human papillomavirus and oral cancer: the international agency for research on cancer multicenter study. Journal of the National Cancer Institute, 95, 2003, 23, s. 1772-1783.
18. Chaturvedi, A., Gillison, M. L.: Human papillomavirus and head and neck cancer. In: Epidemiology, Pathogenesis, and Prevention of Head and Neck Cancer (1st ed.). New York, Springer, 2010, ISBN 978-1-4419-1471-2.
19. Chaturvedi, A. K., Engels, E. A., Anderson, W. F. et al.: Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. Journal of Clinical Oncology, 26, 2008, 4, s. 612-619.
20. Chaturvedi, A. K., Engels, E. A., Pfeiffer, R. M. et al.: Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J. Clin. Oncol.. 29, 2011, 32, s. 4294-4301.
21. Kašpírková, J., Ondič, O., Černá, K. et al.: Možnosti průkazu biologicky relevantní papilomavirové infekce u maligních nádorů hlavy a krku v diagnostické patologii. Cesk. Patol., 49, 2013, 1, s. 29-34.
22. Klozar, J., Koslabova, E., Kratochvil, V. et al.: Nodal status is not a prognostic factor in patients with HPV-positive oral/oropharyngeal tumors. J. Surg. Oncol., 107, 2013, 6, s. 625-633.
23. Klozar, J., Tachezy, R.: What are the implications of human papillomavirus status in oropharyngeal tumors for clinical practice? Curr. Opin. Otolaryngol. Head Neck Surg., 22, 2014, 2, s. 90-94.
24. Klussmann, J. P., Weissenborn, S. J., Wieland, U. et al.: Prevalence, distribution, and viral load of human papillomavirus 16 DNA in tonsillar carcinomas. Cancer, 92, 2001, 11, s. 2875-2884.
25. Koslabova, E., Hamsikova, E., Salakova, M. et al.: Markers of HPV infection and survival in patients with head and neck tumors. Int. J. Cancer. 133, 2013, s.1832-1839.
26. Kreimer, A. R., Bhatia, R. K., Messeguer, A. I. et al.: Oral human papillomavirus in healthy individuals: A Systematic Review of the Literature. Sexually Transmitted Diseases, 37, 2010, 6, s. 386-391.
27. Kreimer, A. R., Clifford, G. M., Boyle, P. et al.: Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systemic review. Cancer Epidemiology Biomarkers and Prevention, 14, 2005, 2, s. 467-475.
28. Kreimer, R., Johansson, M., Waterboer, T. et al.: Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. J. Clin. Oncol., 31, 2013, s. 2708-2715.
29. Laco, J.: Lidské papilomaviry a jejich úloha v etiopatogenezi dlaždicobuněčného karcinomu dutiny ústní a orofaryngu. Praha, Galén, 2012, s. 70-73.
30. Lassen, P., Eriksen, J. G., Hamilton-Dutoit, S. et al.: Effect of HPV-associated p16 expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. Journal of Clinical Oncology, 27, 2009, 12, s. 1992-1998.
31. Licitra, L., Perrone, F., Bossi, P. et al.: High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. Journal of Clinical Oncology, 24, 2006, 36, s. 5630-5636.
32. Lu, B., Kumar, A., Castellsague, X. et al.: Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis. BMC Infect Dis., 2011, s. 11-13.
33. Machtay, M., Moughan, J., Trotti, A. et al.: Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. Journal of Clinical Oncology. 26, 2008, 21, s. 3582-3589.
34. Marur, S. et al.: ASCO annualm meeting, JCO, 2013. E1308: A phase II trial of induction chemotherapy (IC) followed by cetuximab with low dose versus standard dose IMRT in patients with human papilloma virus (HPV) -associated resectable squamous cell carcinoma of the orophayrnx (OPSCC). Suppl, s. 6005.
35. Marur, S., D'Souza, G., Westra, W. H. et al.: HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol., 11, 2010, 8, s. 781-789.
36. Mellin, H., Friesland, S., Lewensohn, R. et al.: Human papillomavirus (HPV) DNA in tonsillar cancer: clinical correlates, risk of relapse, and survival. Int. J. Cancer, 89, 2000, 3, s. 300-304.
37. Neuwirthová, J., Smilek, P., Gál, B. et al.: Patogeneze kancerogenity etanolu u karcinomů hlavy a krku. Onkologie, Olomouc, Solen, 2014, ISSN 1802-4475.
38. O’Sullivan, B., Huang, S. H., Siu, L. L. et al: Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J. Clin. Oncol., 31, 2013, s. 543-550.
39. Oldenburg, O. S., Moore, J. E., Van Abel, K. et al.: Human papillomavirus associated oropharyngeal squamous cell carcinoma: proposal fot a new staging systemNG SYSTEM. http://ahns.jnabstracts.com/Detail.aspx?ID=56440. [Online].
40. Olthof, N. C., Speel, E. J., Kolligs, J. et al.: Comprehensive analysis of HPV16 integration in OSCC reveals no significant impact of physical status on viral oncogene and virally disrupted human gene expression. PLOS One., 9, 2014, 2, s. 24.
41. Palefsky, J.: Human papillomavirus-related disease in people with HIV. Current Opinion in HIV and AIDS, 4, 2009, 1, s. 52-56.
42. Parkin, D. M., Whelan, S. L., Ferlay, J. et al.: Cancer Incidence in five continents, 8, 2002.
43. Rotnáglová, E., Tachezy, R., Saláková, M. et al.: HPV involvement in tonsillar cancer: prognostic significance and clinically relevant markers. Int. J. Cancer, 129, 2011, 1, s. 101-110.
44. Smith, E. M., Ritchie, J. M., Summersgill, K. F. et al: Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers. International Journal of Cancer, 108, 2004, 5, s. 766-772.
45. Smith, E. M., Rubenstein, L. M., Haugen, T. H. et al.: Tobacco and alcohol use increases the risk of both HPV-associated and HPV-independent head and neck cancers. Cancer Causes and Control, 21, 2010, 9, s. 1369-1378.
46. Spanos, W. C., Nowicki, P., Lee, D. W. et al.: Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer. Archives of Otolaryngology-Head and Neck Surgery, 135, 2009, 11, s. 1137-1146.
47. Sturgis, E. M., Cinciripini, P. M.: Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers . Cancer, 110, 2007, 7, s. 1429-1435.
48. Tachezy, R., Klozar, J., Saláková, M. et al.: HPV and other risk factors of oral cavity/oropharyngeal cancer in the Czech Republic. Oral Dis., 11, 2005, s. 181-185.
49. Trotti, A., Gillison, M.: Phase III trial of radiotherapy plus cetuximab versus chemoradiotherapy in HPV. Associated Oropharynx Cancer. http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=1016.
50. Wilczynski, S. P., Lin, B. T. Y., Xie, Y. et al.: Detection of human papillomavirus DNA and oncoprotein overexpression are associated with distinct morphological patterns of tonsillar squamous cell carcinoma. American Journal of Pathology, 152, 1998, 1, s. 145-156.
51. Zwenger, S. R.: Bogarting that joint might decrease oral hpv among cannabis users. Curr. Oncol., 16, 2009, 6, s. 5-7.
Labels
Audiology Paediatric ENT ENT (Otorhinolaryngology)Article was published in
Otorhinolaryngology and Phoniatrics
2015 Issue 4
Most read in this issue
- Inflammatory Pseudotumor of Temporal Bone
- Increasing Incidence of HPV Related Oropharyngeal Cancers
- Psychogenic Disorder on Hearing in Children
- Papillary Carcinoma in a Medial Cervical Cyst